Based on crucial roles of RAS in the pathogenic development of chronic kidney disease (CKD), we tested the hypothesis whether plasma ACE and ACE2 levels might be significantly changed in the patients with end-stage CKD (ESRK), i.e., uremic patients. Here, ACE2 is linked to chronic kidney disease.